Merck begins early stage trial of cardiovascular drug
‘Merck & Co has initiated a phase I clinical trial of an orally administered drug candidate, being developed in partnership with Arena Pharmaceuticals, for the treatment of atherosclerosis.
The initiation of the early stage trial triggers a $2 million milestone payment to Arena under its cardiovascular disease collaboration with Merck to develop compounds targeted at a G protein-coupled receptor, or GPCR, that has the potential to regulate plasma fat profiles, including the “good” cholesterol.’
Read more at Merck begins early stage trial of cardiovascular drug
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax